This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Enzo Biochem Reports Improved Second Quarter Results

Stocks in this article: ENZ

Enzo Biochem Inc. (NYSE:ENZ) today reported improved results for the fiscal quarter ended January 31, 2012. Among the quarter’s highlights:

  • Total revenues increased 5% year over year, led by strong organic growth at Enzo Clinical Labs and increased royalty and licensee income;
  • Gross margin was up 12%;
  • Operating results improved by $1.5 million;
  • Approval received by New York State Department of Health for ColonSentry, a proprietary assay for assessment of a patient’s risk of having colorectal cancer;
  • AmpiProbe™ HCV Assay, first of Company’s proprietary nucleic acid amplification technology, to be unveiled at leading European medical meeting.

“The quarter was another period of progress, both on the operational and development fronts. Enzo Clinical Labs posted another quarter of strong organic growth. At Enzo Life Sciences margins have begun improving as our efforts to streamline the product mix, improve marketing and enhance manufacturing start to yield results. Our recent announcements related to molecular diagnostics further support our progress in the development of novel assays that hold promise to contribute to the advancement of healthcare,” said Barry Weiner, President.

Second Quarter Results

Revenues for the second fiscal quarter were $25.0 million, compared with $23.7 million a year ago, an increase of 5%, as a result of both continued growth at Enzo Clinical Labs and an increase in royalty and licensing fee income. Gross profit improved to 46%, from 44% year over year. Operating expenses declined $0.5 million to $15.4 million, due to a reduction in legal and R&D expenses, partially offset by an increased provision for uncollectible accounts receivable due to higher service volume at Enzo Clinical Labs. However, the Company increased its developmental effort in the area of new molecular tests and technology platform development. Selling, general and administrative expenses as a percentage of revenues declined to 46% from 49% in the year ago period. The net loss for the period was reduced by $1.5 million or ($.04) per diluted share, declining to $4.2 million or ($.11) loss per diluted share. EBITDA loss was lower by $1.4 million or 32% to $3.0 million. Total cash used was $2.8 million, which included a non-recurring cash payment of $1.1 million for the final earn-out from a previous acquisition and cash used in operations of $1.3 million.

1 of 5

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 18,053.71 +23.50 0.13%
S&P 500 2,088.77 +6.89 0.33%
NASDAQ 4,806.8590 +33.3870 0.70%

Brokerage Partners

Rates from

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs